Abstract: Methods of detecting and treating rapidly growing exogenous cells, such as Protista, or parasites, that preferentially accumulate a photoactivatable porphyrin in which 5-aminolevulinic acid or precursor thereof is administered to the patient, or contacted to the exogenous cells, in an amount sufficient to induce synthesis fluorescence and/or photosensitizing concentrations of a protoporphyrin IX in the exogenous cells, followed by exposure of the exogenous cells to light of photoactivating wavelengths.
Abstract: An oral composition which is adapted to be dispersed in an aqueous carrier substantially immediately prior to administration comprises a multiplicity of particles comprising an active substance, the particles being combined with one or more gelling or swelling agents capable of forming a viscous medium around the particles in an aqueous carrier as well as being provided with a masking surface layer when dispersed in the aqueous carrier. This serves to mask uneven surfaces on the particles and prevent them from adhering to oral mucosa when the composition is ingested and thus makes it easier to administer large dosages of an active substance. The masking surface layer is preferably provided by an increased viscosity of the viscous medium in the immediate vicinity of the particles relative to the viscosity of the surrounding aqueous carrier. A ready-to-use composition is prepared by mixing the composition with an aqueous carrier substantially immediately prior to administration of the composition.
Abstract: Patients with symptomatic HIV infection, including AIDS and ARC are treated to increase appetite and to cause a reduction in loss of weight. The delta-9-tetrahydrocannabinol may be administered orally, in capsules, or in tablets, or by injection, suppository, intranasal, transdermal, inhalant or sublingual administration.
Abstract: An external composition containing a silicone-modified polysaccharide compound and a low viscosity silicone oil and/or powder component, which is useful for covering rough surfaces on a skin.
Abstract: Methods and novel intermediates for the preparation of and the treatment with acyclic nucleoside derivatives of the formula:
where one of R1 and R2 is an amino acid acyl group and the other of R1 and R2 is a —C(O)C3-C21 saturated or monounsaturated, optionally substituted alkyl and
R3 is OH or H.
Abstract: A method for performing retinal membrane removal is disclosed using vital dyes which are applied to the membrane. Compositions including vital dyes which are useful in the retinal membrane removal methods are also disclosed.
Abstract: The combination of the HIV protease inhibitor Compound J, 3TC, and, optionally AZT, ddI, or ddC, is useful in the inhibition of HIV protease, the inhibition of HIV reverse transcriptase, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
Type:
Grant
Filed:
February 1, 1995
Date of Patent:
February 10, 2004
Assignee:
Merck & Co., Inc.
Inventors:
Jeffrey A. Chodakewitz, Emilio A. Emini
Abstract: The present invention is directed to the use of antiviral compounds having the following generalized structure:
wherein R is 2H or ═O; R′ is OH, H, or COOH (single substitution); and R″ is OH, H, or alkyl; and pharmaceutically acceptable salts thereof as therapeutic substances having antiviral activity against human cytomegalovirus (“HCMV”) and for treating diseases caused by HCMV. Dimeric forms of the forgoing antiviral compounds having antiviral activity against HCMV are also disclosed. Pharmaceutical compositions containing the disclosed antiviral compounds are disclosed for topical and systemic administration.
Abstract: The use of a compound of formula (A) or a bioprecursor, or a pharmaceutically acceptable salt, phosphate ester and/or acyl derivative of either of the foregoing for use in the prophylactic treatment of HHV-6 infection.
Type:
Grant
Filed:
February 16, 2000
Date of Patent:
January 27, 2004
Assignee:
Novartis International Pharmaceutical Ltd.
Inventors:
Richard Anthony Vere Hodge, Malcolm Richard Boyd
Abstract: A novel solid pharmaceutical dispersion that improves the bioavailability of poorly water soluble drugs is produced by combining the drug with a polymer carrier such as polyvinylpyrrolidone. The drug is combined with the carrier without the need for using organic solvents or melting temperatures (fusion) through the use of a transition compound such as polyethylene glycol which partially solubilizes the drug and/or plasticizes the polymer.
Type:
Grant
Filed:
March 28, 1994
Date of Patent:
January 13, 2004
Assignee:
Warner-Lambert Company
Inventors:
Isaac Ghebre-Sellassie, Robert Reisch, Jr., Riten Parikh, Mahdi B. Fawzi, Russell U. Nesbitt
Abstract: An improved method of treating skin diseases comprises applying to the skin of a patient suffering such a skin disease an allantoin-containing composition in a therapeutically effective quantity. The allantoin-containing composition is a water-in-oil emulsion that includes allantoin and an emulsifier system that includes at least one emulsifier that is either an anionic emulsifier or a nonionic emulsifier. If the emulsifier is an anionic emulsifier, the emulsifier system can include beeswax. The nonionic emulsifiers used can include at least one nonionic emulsifier that is an ethoxylated ether or an ethoxylated ester whose carbon chain length ranges from 8 to 22 carbon atoms. Alternatively, the emulsifier system can include an acidic anionic polymer such as carboxypolymethylene and an anionic emulsifier. In another alternative, the emulsifier system can include the acidic anionic polymer and a nonionic emulsifier, or the acidic anionic polymer alone.
Abstract: This invention relates to methods for transdifferentiation of body tissues which can be used to generate specific cell types needed for regenerating organs or body parts, following cellular degeneration, injury or amputation. The present invention also describes the use of tissue transdifferentiation for treating cancer and autoimmune diseases.
Abstract: A method for attenuating the HIV-associated myopathy and muscle wasting associated with infection by human immunodeficiency virus-Type 1. Administration of oxandrolone in a daily dosage of about 2.5 to about 20 milligrams is described.
Abstract: Linear or cyclic diorganosiloxane compounds that include at least one nitroaniline function are disclosed; the compounds may be used as organic dyes in cosmetic compositions suitable for dyeing human keratin fibers, especially hair, or for make-up. The dyes may also be used in foods and pharmaceutical compositions and for dyeing natural and synthetic fibers and plastics or inorganic materials. Also disclosed are the use of the compounds in the above-mentioned fields, cosmetic compositions containing such compounds, and a method for directly dyeing keratin fibers.
Abstract: A composition for use by animals, including humans, to alleviate pain and/or inflammation around a painful joint, joint replacement surgery site, muscle, tendon, and/or ligament. A method to ameliorate pain and/or inflammation in or around a joint, muscle, tendon, and/or ligament, by topically applying Applicant's composition.
Abstract: This galenical formulation which comprises first an outer envelope including gelatin and secondly a non-aqueous liquid or semi-liquid internal phase containing an active principle in solution is characterized in that the active principle is constituted by a spermicide and in that the internal phase includes, in addition to the active principle: a major proportion of a lipophilic agent compatible with the rubber latex of a condom; in minor proportion at least one hydrodispersible agent; at least one bioadhesion agent; and at least one agent for gelling the lipophilic agent. This galenical formulation for vaginal use provides the known advantages of the soft capsule, having properties that are simultaneously spermicidal, antiseptic, and lubricating, and in addition it is reliably compatible with condoms, without any risk of damaging the rubber latex thereof.
Abstract: A novel powder composition comprised of a skin irritation reducing agent comprising 1-Carboxy-N,N,N-trimethylmethanaminium hydroxide inner salt, Scutellaria baicalensis extract, bisabolol, or mixtures thereof. Also provided is a method for treating prickly heat comprised of topically applying an effective amount of the powder to a desired area.
Type:
Grant
Filed:
February 22, 2002
Date of Patent:
December 9, 2003
Assignee:
Johnson & Johnson Consumer Companies, Inc
Inventors:
Attaya Nitikhunkasem, Alain V. Khaiat, John Hopkins
Abstract: Methods for treating lipid storage diseases using compounds that inhibit glucosyltransferase enzymes are disclosed herein. The invention relates to the treatment of lipid storage disease with compounds that inhibit glucosyltransferase activity in the affected cells. It relates particularly to the use of 1,5-dideoxy-1,5-imino-D-glucitol and derivatives thereof.
Type:
Grant
Filed:
September 17, 2002
Date of Patent:
December 9, 2003
Assignee:
Chancellor, Masters and Scholars of the University of
Oxford
Inventors:
Terry D. Butters, Frances M. Platt, Raymond A. Dwek